<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03931954</url>
  </required_header>
  <id_info>
    <org_study_id>D2287R00140</org_study_id>
    <nct_id>NCT03931954</nct_id>
  </id_info>
  <brief_title>Prevalence of the Eosinophilic Phenotype Among Severe Asthma Patients</brief_title>
  <acronym>PREPARE</acronym>
  <official_title>PREPARE STUDY: PRevalence of the Eosinophilic Phenotype Among SeveRE Asthma Patients in AstraZeneca International Region. A Multinational, Cross-Sectional, Multicenter Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this cross-sectional, multicenter study is to determine the prevalence of an&#xD;
      eosinophilic phenotype of blood eosinophil count ≥ 300 cells/mm3 among severe asthma patients&#xD;
      who attend to sites specialized in the management of severe asthma in several countries in&#xD;
      the AstraZeneca International Region. The prevalence of an atopic phenotype and asthma&#xD;
      control, will also be studied.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To determine the prevalence of an eosinophilic phenotype of blood eosinophil count ≥ 300&#xD;
      cells/mm3 among severe asthma patients attending their routine clinical visit at sites&#xD;
      specialized in the management of severe asthma in several countries in the AstraZeneca&#xD;
      International Region. The prevalence of an atopic phenotype and the status of asthma control,&#xD;
      will also be studied. It is expected that this study will contribute to the understanding of&#xD;
      severe asthma, ultimately helping to inform therapeutic decisions and addressing patients'&#xD;
      needs.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 15, 2019</start_date>
  <completion_date type="Actual">November 26, 2020</completion_date>
  <primary_completion_date type="Actual">November 26, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Blood Eosinophil count</measure>
    <time_frame>There is only one study visit. During that study visit the sample will be collected</time_frame>
    <description>The level of eosinophils in the blood will be assessed from this blood sample and reported</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total serum IgE</measure>
    <time_frame>There is only one study visit. during that visit the sample will be collected</time_frame>
    <description>Total serum IgE will be assessed from this blood sample and reported</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">794</enrollment>
  <condition>Severe Asthma</condition>
  <arm_group>
    <arm_group_label>Study population</arm_group_label>
    <description>Patients completing the inclusión criteria</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        The study population will include patients from 12 years and older with severe asthma, as&#xD;
        per the definition of the GINA 2018 Guidelines (GINA, 2018). Patients will be identified&#xD;
        and invited to participate in the study consecutively, as they attend their routine&#xD;
        clinical visit at the research centers.&#xD;
&#xD;
        To be included in the study, each patient should meet all the inclusion criteria and none&#xD;
        of the exclusion criteria described in the sections below. Patients should provide written,&#xD;
        informed consent prior to any study-specific procedures.&#xD;
&#xD;
        The enrolment period will be approximately 8 months or until the required number of&#xD;
        patients has been included, whichever occurs first&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Patients must fulfil all of the following inclusion criteria to be included in the study:&#xD;
&#xD;
          -  Male or female patient, aged 12 years or older by the time of study entry&#xD;
&#xD;
          -  Patient visiting a participating center for a routine clinical appointment&#xD;
&#xD;
          -  Patient is willing and able to provide a blood sample for IgE and eosinophil levels&#xD;
             determination as part of their routine clinical visit&#xD;
&#xD;
          -  Diagnosis of severe asthma for at least one year as defined by:&#xD;
&#xD;
          -  Treatment with guidelines-suggested medications for Global Initiative for Asthma (3)&#xD;
             steps 4-5 asthma&#xD;
&#xD;
          -  Patients or their legal guardian, who voluntarily sign and date the informed consent&#xD;
             form prior to study entry.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Patients with a diagnosis of chronic obstructive pulmonary disease or other chronic&#xD;
             respiratory condition beyond severe asthma&#xD;
&#xD;
          -  An acute or chronic condition that, in the investigator's opinion, would limit the&#xD;
             patient's ability to participate in this study Patients who are currently under a&#xD;
             biologic therapy to treat their severe asthma&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maarten beekman, MD</last_name>
    <role>Study Chair</role>
    <affiliation>medical lead respiratory International</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Monica Olmos, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Study delivery lead</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rosario</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Curico</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Barranquilla</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bogota</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bucaramanga</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pereira</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Jose</city>
        <country>Costa Rica</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Guadalajara</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Merida</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Puebla</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Juan Del Rio</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Villahermosa</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dammam</city>
        <country>Saudi Arabia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jeddah</city>
        <country>Saudi Arabia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Riyadh</city>
        <zip>111511</zip>
        <country>Saudi Arabia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Riyadh</city>
        <country>Saudi Arabia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Chile</country>
    <country>Colombia</country>
    <country>Costa Rica</country>
    <country>Mexico</country>
    <country>Saudi Arabia</country>
  </location_countries>
  <removed_countries>
    <country>Hong Kong</country>
    <country>Lebanon</country>
  </removed_countries>
  <link>
    <url>https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;amp;parentIdentifier=D2287R00140&amp;amp;attachmentIdentifier=706cb728-2854-4287-a5b9-0d84bcd0a71c&amp;amp;fileName=CSR_PREPARE_V_0.5_CTT_with_Milestones_Combined.pdf&amp;amp;versionIdentifier=</url>
    <description>CSR Synopsis</description>
  </link>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>April 10, 2019</study_first_submitted>
  <study_first_submitted_qc>April 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 30, 2019</study_first_posted>
  <last_update_submitted>January 28, 2021</last_update_submitted>
  <last_update_submitted_qc>January 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>eosinophilic asthma</keyword>
  <keyword>severe asthma</keyword>
  <keyword>prevalence</keyword>
  <keyword>phenotype</keyword>
  <keyword>atopic phenotype</keyword>
  <keyword>eosinophilic phenotype</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

